Browse the evidence

GLP1R agonists (like liraglutide) suppress food intake by acting on LepRbGlp1r neurons, but this pathway alone is insufficient for significant body weight loss.

GLP-1 drugs like liraglutide work partly by activating a specific brain pathway (LepRbGlp1r) that tells you to eat less. However, this pathway alone doesn't account for all the weight loss, meaning other brain areas are also involved. This suggests these drugs are complex and work on multiple levels.

Using assumed or estimated menstrual cycle phases (e.g., calendar-based counting) instead of direct biochemical verification (e.g., LH surge, progesterone levels) produces invalid and unreliable data in sport-related research.

Do not use calendar-based methods or apps to assign menstrual cycle phases in research or applied practice without biochemical verification. To accurately determine phases (e.g., follicular vs. luteal), you must measure biological markers such as urinary luteinizing hormone (LH) surges and serum/saliva progesterone levels. Relying on calendar counting alone is scientifically invalid due to high inter- and intra-individual variability in ovulation timing and the prevalence of subtle menstrual disturbances.

GLP-1 receptor agonists do not significantly increase the overall risk of cardiac arrhythmias (atrial fibrillation, atrial flutter, ventricular arrhythmias, or sudden cardiac death) in patients with type 2 diabetes or obesity compared to controls.

For patients with Type 2 Diabetes or Obesity, GLP-1 medications (like Ozempic, Trulicity, or Wegovy) are generally safe regarding heart rhythm. While they may slightly increase your resting heart rate, large studies show they do not increase the risk of serious heart rhythm problems like atrial fibrillation or ventricular arrhythmias compared to other treatments. However, those with very high BMI or on high doses should be monitored for ventricular arrhythmias.

Ketogenic diets are not recommended for Type 1 Diabetes or Gestational Diabetes due to safety concerns, lack of long-term data, and potential risks of DKA and fetal harm.

Do not use a ketogenic diet for Type 1 Diabetes or Gestational Diabetes. The risks of Diabetic Ketoacidosis (DKA) and potential harm to fetal development outweigh any potential glycemic benefits. Follow standard medical advice for these conditions.

Elevated plasma levels of endotrophin, the C-terminal cleavage product of collagen type VI alpha 3 (COL6A3), causally increase the risk of coronary artery disease, acting as a primary mediator linking obesity to cardiometabolic disease.

Obesity increases the risk of heart disease partly by raising levels of a specific protein fragment called endotrophin. This fragment is created when body fat increases, specifically from abdominal subcutaneous fat. The good news is that losing body fat reduces these levels. Therefore, weight loss interventions that reduce abdominal adiposity are likely to lower this specific biological risk factor for coronary artery disease.

Dapagliflozin (10 mg daily) improves cardiometabolic outcomes in patients hospitalized for myocardial infarction, regardless of diabetes status, by reducing the risk of heart failure hospitalization and death.

If you have had a heart attack, even if you don't have diabetes, taking dapagliflozin (10 mg daily) alongside your standard heart medications can significantly improve your recovery outcomes. It reduces the risk of future heart failure hospitalizations and death. The benefit is seen regardless of your diabetes status.

Bempedoic acid (180 mg daily) reduces major adverse cardiovascular events (MACE) in high-risk patients who are unable or unwilling to take statins, primarily by lowering LDL cholesterol and reducing coronary revascularization needs.

If you have high cholesterol and a history of heart disease but cannot take statins due to side effects, bempedoic acid (180 mg daily) is an effective alternative. It lowers LDL cholesterol and significantly reduces your risk of heart attack, stroke, and the need for coronary procedures. It is taken once daily.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of Heart Failure (HF) in a bodyweight-dependent manner, but also confer class-specific benefits beyond what is explained by weight or HbA1c changes alone.

If you have type 2 diabetes and are at risk for heart failure, SGLT2 inhibitors are the preferred class of medication. They reduce heart failure risk by 32% overall. This benefit comes from both weight loss (7% risk reduction per kg lost) and unique heart-protective effects that work even without significant weight change.

Obesity-related hypertension is mechanistically driven by visceral fat accumulation, leading to SNS and RAAS activation, sodium retention, and inflammation, which directly causes CKD progression.

Visceral fat is not just storage; it actively drives high blood pressure and kidney damage through hormones and inflammation. Managing visceral fat is key to preventing kidney disease.

Modifying the glycemic index of a high-quality dietary pattern (like DASH) does not improve cardiovascular risk factors or insulin sensitivity compared to a high-GI version of the same pattern.

Do not assume that choosing 'low GI' versions of healthy foods (like low-GI pasta or bread) offers extra cardiovascular benefits over standard versions if the overall diet is already healthy. Focus on the quality of the entire diet (e.g., DASH or Mediterranean patterns) rather than optimizing for glycemic index.

Metabolic bariatric surgery (MBS) is the most effective intervention for achieving long-term and sustained weight loss and can reverse certain metabolic defects like insulin resistance by altering gut hormone secretion.

For severe obesity, lifestyle changes alone are often insufficient. Metabolic bariatric surgery (like gastric bypass) is currently the most effective treatment for long-term weight loss and can reverse metabolic issues like diabetes by changing gut hormones.

Obesity is a chronic, progressive, relapsing, multifactorial neurobehavioral disease driven by complex brain-gut-adipose interactions, not merely a lack of willpower.

Stop blaming yourself for your weight. Obesity is a biological disease involving hormones and brain signaling, not a character flaw. Seek medical care that treats the underlying biology, not just willpower.

Obesity is associated with increased risk of various cancers (breast, colorectal, endometrial, etc.) through mechanisms involving chronic inflammation, insulin resistance, and hormonal changes.

Maintaining a healthy weight reduces your risk of several cancers. Focus on sustainable lifestyle changes to lower your risk.

GLP-1 receptor agonists significantly increase the volume of retained gastric contents in fasting patients, but this does not translate to a statistically significant increase in actual pulmonary aspiration rates.

If you take a GLP-1 drug (like Ozempic or Wegovy) and have surgery, your stomach might stay fuller longer, but you are not significantly more likely to vomit into your lungs than someone who doesn't take it. Do not stop your medication without asking your surgeon or anesthesiologist, as modern guidelines suggest continuing it for most people while using other safety checks like ultrasound.

Endogenous GIP acts as an incretin that potentiates glucose-stimulated insulin secretion, and its inhibition via GIP receptor antagonists reveals this physiological role.

GIP naturally helps your body release insulin after eating. Early treatments tried adding more GIP, but it didn't work well in diabetics. New research shows that blocking GIP's natural signal helps scientists understand its true role, which is still to boost insulin, even in diabetes.

Tirzepatide is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) compared to placebo, insulin, and GLP-1 RAs, particularly at higher doses.

Expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but often improve over time. Discuss management strategies with your doctor.

Higher fasting insulin levels and lower Sex Hormone-Binding Globulin (SHBG) levels causally increase the risk of PCOS, acting as key metabolic drivers of the syndrome.

Managing insulin resistance is crucial for PCOS prevention and management. High insulin and low SHBG are causal factors. Lifestyle interventions that improve insulin sensitivity (diet, exercise) can mitigate PCOS risk by addressing these metabolic drivers.

Obesity is a neurobiological disorder driven by genetic and environmental interactions that dysregulate brain-controlled energy homeostasis, rather than a failure of individual willpower.

Understand that obesity is a complex biological condition influenced by genetics and environment, not a simple failure of willpower. This perspective shifts the focus from self-blame to seeking effective, biologically-targeted treatments and lifestyle adjustments that work with your body's natural regulatory systems.

Hyperglycemia and insulin resistance drive Coronary Microvascular Dysfunction (CMD) through oxidative stress, inflammation, and reduced nitric oxide (NO) bioavailability, leading to endothelial dysfunction.

Controlling blood sugar and insulin resistance is critical not just for nerves and kidneys, but for heart health. High glucose and insulin resistance directly damage the heart's small blood vessels by creating oxidative stress and reducing the body's ability to dilate blood vessels (NO bioavailability).

GLP-1 receptor agonists are associated with an increased risk of gastrointestinal side effects (nausea, vomiting, diarrhea) and rare serious adverse events (gallbladder disorders, pancreatitis), as well as emerging risks related to delayed gastric emptying affecting anesthesia and endoscopy.

Be aware that nausea, vomiting, and diarrhea are common when starting GLP-1 medications, but they often improve over time. Serious side effects like gallbladder issues or pancreatitis are rare but require medical attention. If you need surgery or a colonoscopy, inform your provider, as they may need to adjust your medication schedule to prevent complications like aspiration.

GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.

GLP-1 medications do more than help you lose weight; they actively protect your heart and kidneys. For people with diabetes or existing heart/kidney issues, these drugs significantly lower the risk of heart attacks, strokes, and kidney failure. This protection is a key reason why doctors prescribe them, offering benefits beyond just the scale.

Enteroendocrine cells (EECs) act as chemosensors that secrete hormones (e.g., GLP-1, PYY, CCK) in response to luminal nutrients, regulating appetite, glucose metabolism, and gut motility.

Your gut contains specialized cells that sense what you eat and send signals to your brain and pancreas to regulate hunger and blood sugar. This natural system can be targeted by medications to treat metabolic diseases.

Long-term weight loss maintenance is physiologically opposed by metabolic adaptation (reduced energy expenditure) and hyperphagia (increased appetite), driven by neuroendocrine signals like leptin, making weight regain the default biological state.

Understand that after weight loss, your body biologically fights to regain weight through increased hunger and slower metabolism. This is not a failure of willpower but a physiological defense. Successful maintenance requires acknowledging this biological reality and often necessitates ongoing, lifelong behavioral or medical support to counter these natural drives.

The hypothalamus regulates body fat mass through a defended set point, where afferent signals from gut hormones (GLP-1, CCK, ghrelin) and adipose tissue (leptin) modulate food intake and energy expenditure.

Your brain uses signals from your gut (like GLP-1 and ghrelin) and fat cells (leptin) to decide how hungry you are and how much energy you burn. In obesity, this system is broken, defending a higher weight.